These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20089977)

  • 21. Toxin-mediated paracellular transport of antitoxin antibodies facilitates protection against Clostridium difficile infection.
    Zhang Z; Chen X; Hernandez LD; Lipari P; Flattery A; Chen SC; Kramer S; Polishook JD; Racine F; Cape H; Kelly CP; Therien AG
    Infect Immun; 2015 Jan; 83(1):405-16. PubMed ID: 25385797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple relapses of Clostridium difficile-associated diarrhea responding to an extended course of cholestyramine.
    Pruksananonda P; Powell KR
    Pediatr Infect Dis J; 1989 Mar; 8(3):175-8. PubMed ID: 2496393
    [No Abstract]   [Full Text] [Related]  

  • 23. Fidaxomicin for Clostridium difficile Infection.
    Safdar N; Craig WA
    N Engl J Med; 2011 May; 364(19):1875; author reply 1875-6. PubMed ID: 21561360
    [No Abstract]   [Full Text] [Related]  

  • 24. IgG antibody response to toxins A and B in patients with Clostridium difficile infection.
    Wullt M; Norén T; Ljungh A; Åkerlund T
    Clin Vaccine Immunol; 2012 Sep; 19(9):1552-4. PubMed ID: 22787196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
    Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV
    Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reevaluation of the Premier Clostridium difficile toxin A and B immunoassay with comparison to glutamate dehydrogenase common antigen testing evaluating Bartels cytotoxin and Prodesse ProGastro Cd polymerase chain reaction as confirmatory procedures.
    Doing KM; Hintz MS; Keefe C; Horne S; LeVasseur S; Kulikowski ML
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):129-34. PubMed ID: 20117349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
    Kyne L; Warny M; Qamar A; Kelly CP
    N Engl J Med; 2000 Feb; 342(6):390-7. PubMed ID: 10666429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of toxin A negative/B positive Clostridium difficile strains.
    Webb KH
    J Hosp Infect; 2000 Aug; 45(4):331-2. PubMed ID: 10973753
    [No Abstract]   [Full Text] [Related]  

  • 29. Lacking the incentive to cure? Recurring Clostridium difficile diarrhea and our reluctance to use fecal transplantation.
    Ho N; Prasad V
    J Clin Gastroenterol; 2011 Apr; 45(4):379-80. PubMed ID: 21278582
    [No Abstract]   [Full Text] [Related]  

  • 30. Diagnosis of Clostridium difficile-associated intestinal disease.
    Rolfe RD
    Crit Rev Clin Lab Sci; 1986; 24(3):235-61. PubMed ID: 3539522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dioctahedral smectite neutralization activity of Clostridium difficile and Bacteroides fragilis toxins in vitro.
    Martirosian G; Rouyan G; Zalewski T; Meisel-Mikołajczyk F
    Acta Microbiol Pol; 1998; 47(2):177-83. PubMed ID: 9839376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enterotoxin A of Clostridium difficile and alpha-Gal epitopes.
    Pothoulakis C
    Subcell Biochem; 1999; 32():215-27. PubMed ID: 10391997
    [No Abstract]   [Full Text] [Related]  

  • 33. Co-culture with potentially probiotic microorganisms antagonises virulence factors of Clostridium difficile in vitro.
    Trejo FM; Pérez PF; De Antoni GL
    Antonie Van Leeuwenhoek; 2010 Jun; 98(1):19-29. PubMed ID: 20232250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice.
    Seregin SS; Aldhamen YA; Rastall DP; Godbehere S; Amalfitano A
    Vaccine; 2012 Feb; 30(8):1492-501. PubMed ID: 22200503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is "negative" positive?
    Surawicz CM
    Am J Gastroenterol; 1999 Oct; 94(10):3060-1. PubMed ID: 10520871
    [No Abstract]   [Full Text] [Related]  

  • 36. Which specimens should be tested for Clostridium difficile toxin?
    Berrington A; Settle CD
    J Hosp Infect; 2007 Mar; 65(3):280-2. PubMed ID: 17275962
    [No Abstract]   [Full Text] [Related]  

  • 37. Neutralizing hospital-acquired infections.
    Harrington M
    Lab Anim (NY); 2011 Sep; 40(10):288. PubMed ID: 22358194
    [No Abstract]   [Full Text] [Related]  

  • 38. Bezlotoxumab for the prevention of Clostridium difficile recurrence.
    Couture-Cossette A; Carignan A; Ilangumaran S; Valiquette L
    Expert Opin Biol Ther; 2017 Nov; 17(11):1439-1445. PubMed ID: 28805081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Relation between isolation of bacteriophages from Clostridium difficile and cytotoxicity of the strains].
    Bernabeu A; Iniesta A; Martín Luengo F
    Enferm Infecc Microbiol Clin; 1991 May; 9(5):289-91. PubMed ID: 1954265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toxin A-negative, toxin B-positive Clostridium difficile.
    Drudy D; Fanning S; Kyne L
    Int J Infect Dis; 2007 Jan; 11(1):5-10. PubMed ID: 16857405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.